SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Facade of Takeda's office in Massachusetts
Business
Takeda Reports Lower Profits in Latest Quarter, Closes $300M Deal with Protagonist
The Japanese pharma’s financial numbers showed a drop in operating revenue as it signed a $300 million license and collaboration agreement with Protagonist Therapeutics.
February 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Merck Research Laboratories headquarters in Silicon Valley
Business
Merck Posts $60B in Sales for 2023 Driven by Keytruda, HPV Vaccine
The company’s blockbuster cancer treatment Keytruda continues to be a significant boon to its bottom line, according to Merck’s fourth quarter and full-year 2023 financial results.
February 2, 2024
 · 
1 min read
 · 
Tyler Patchen
Syringe resting on top of a vaccine vial, with more vaccine bottles in the background
Vaxcyte Looks to Raise $750M in Latest Public Offering
As Vaxcyte targets it’s the pneumococcal vaccine market, the company is facing significant competition from major pharma companies already in the space.
February 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: AbbVie sign on a building/courtesy of Ad
Business
AbbVie Gets Q4 Beat, Sees 2023 Sales Decline in Oncology and Immunology
While AbbVie beat revenue expectations in the fourth quarter of 2023, the company reported Friday that its overall sales last year declined as it faced biosimilar competition for its blockbuster Humira.
February 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: GSK's headquarters in London
Business
GSK Sees Sales Uptick in 2023 Fueled by Vaccines for RSV and Shingles
The British pharma expects “meaningful” sales and earnings growth in 2024 and is upgrading its growth outlooks for 2026 and 2031, according to GSK CEO Emma Walmsley.
February 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: FDA sign at Washington D.C. headquarters
Policy
FDA Commissioner Says Adcomm Reform, Funding and AI on Agency’s Agenda
During a Wednesday webinar, FDA Commissioner Robert Califf said the agency is working on “systemic” changes to its advisory committee process.
February 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Novo Nordisk's corporate headquarters in Denmark
Business
Novo Nordisk Gets 2023 Profit Beat Fueled by Ozempic, Wegovy Sales Spike
Driven by soaring demand for its diabetes and weight loss drugs, Novo Nordisk on Wednesday reported better-than-expected full-year 2023 earnings with a 31% sales increase.
January 31, 2024
 · 
1 min read
 · 
Tyler Patchen
3d render of cytotoxic CAR exosomes secreted by engineered T immune cells
FDA
Gilead’s Kite Gets FDA Approval for Faster CAR T Therapy Manufacturing
The new FDA-approved manufacturing process for Kite’s CAR-T cell therapy Yescarta will allow a 14-day turnaround compared to 16 days, the company announced on Tuesday.
January 31, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Money growth/iStock, RomoloTavani
Business
Cour Raises $105M in Series A Round with Backing From Big Pharma
The investment in Illinois-based Cour Pharmaceuticals had participation from Bristol Myers Squibb, Pfizer Breakthrough Growth Initiatives and Roche Ventures.
January 31, 2024
 · 
2 min read
 · 
Tyler Patchen
Drug Development
Keep calm and CAR-T on?
Lori, Greg and Tyler discuss last week’s ⁠call for a class-wide box warning⁠ on all commercial CAR T therapies, while investigations are ongoing into ⁠cases of secondary malignancies⁠. How do we approach this ⁠balancing act⁠ of treatment and side effects?
January 31, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Clears Ascidian for First-Ever RNA Editing Trial in US
Ascidian Therapeutics, a member of BioSpace’s NextGen Class of 2024, on Monday announced it received IND clearance from the FDA and was granted Fast Track designation for ACDN-01.
January 30, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: AstraZeneca signage at its office in Sweden
Policy
AstraZeneca, Daiichi’s Enhertu Given FDA Priority Review for Metastatic HER2 Positive Solid Tumors
The FDA has granted Priority Review for AstraZeneca and Daiichi Sankyo’s supplemental BLA for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors.
January 30, 2024
 · 
2 min read
 · 
Tyler Patchen
Gilead's corporate headquarters in Silicon Valley
Business
Gilead Expands Arcus Collaboration with $320M Equity Investment
Gilead Sciences and Arcus Biosciences have amended their collaboration agreement in an effort to accelerate an anti-TIGIT program, the companies announced Monday.
January 30, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Sarepta sign on a brick building/courtes
Drug Development
Sarepta Touts Positive Phase II Results for Next-Gen DMD Treatment
Gene therapy company Sarepta Therapeutics provided additional data for SRP-5051 in treating Duchenne muscular dystrophy patients who are amenable to exon 51 skipping.
January 30, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Nasdaq signage and building in New York City
Deals
Alto Neuroscience, Fractyl Health Join IPO Surge with Detailed Offering Plans
On the heels of ArriVent and CG Oncology’s upsized IPOs last week, Alto Neuroscience and Fractyl Health on Monday announced their respective plans to go public.
January 29, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More